Gilead's patent application was first rejected - just before President Obama's visit in 2015 January - which was seen to be upsetting the U...

Drug-pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has brought under price control revolutionary drug 'Sofosbuvir' pres...

The drug is showing up for sale alongside illegal goods and narcotics on the dark web, which can be accessed through identity-hiding softwa...

Sovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.

Shares of Dr Reddy's Laboratories today settled with gains of nearly 2 per cent after the firm said it is planning to launch Hepatitis C dr...

Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

After surging 19 per cent to its 52-week high at Rs 2,132.60 in intra-day trade, shares of Natco closed at Rs 2,056.85, up by 14.78 per cen...

The company has received approval for generic sofosbuvir tablets in the strength of 400 mg from Drugs Controller General (India).

Natco was the only Indian generic drug maker that had filed a pre-grant patent opposition for the drug with the patent office.

The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them ...

"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.

The decision of the patent office comes at a time when India-US trade relations are seeing an uptick ahead of President Barack Obama’s visi...

It may also to be mentioned that their production of Sovaldi medicines is still in the R&D stages and have not gone into production yet.

The imported drug comes at around Rs 15 lakh a month, taking the cost to Rs 45-50 lakh for a three-month course.

The biggest debate on price cuts is happening in the US with patients, insurers and the government joining in.

Drug companies say that they are not objecting to the control of healthcare costs, but it is the high-handed approach that is harming the i...